INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2019

Vitamin D supplementation did not significantly affect PSA change, PSA response, or mortality in controlled trials of prostate cancer patients.

A systematic review and meta-analysis evaluated 22 clinical trials (16 before-after studies and 6 randomized controlled trials) investigating vitamin D supplementation in patients with prostate cancer. In controlled clinical trials, vitamin D supplementation did not significantly differ from placebo for PSA change from baseline (WMD=-1.66 ng/ml, 95% CI: -0.69 to 0.36, p=0.543), PSA response proportion (RP=1.18, 95% CI: 0.97 to 1.45, p=0.104), or mortality (RR=1.05, 95% CI: 0.81 to 1.36, p=0.713). In single-arm trials, 19% of enrolled patients achieved at least a 50% reduction in PSA by the end of treatment (95% CI: 7% to 31%, p=0.002). The authors concluded that prostate cancer patients do not appear to benefit from high-dose vitamin D supplementation and it should not be recommended for treatment.

Study type
Systematic review and meta-analysis of clinical trials
Who was studied
Patients with prostate cancer across 22 studies (16 before-after, 6 RCTs)
What was measured
PSA change from baseline, PSA response proportion, mortality, side effects

THE PAPER

The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials.

Shahvazi S, Soltani S, Ahmadi SM, de Souza RJ, Salehi-Abargouei A. Horm Metab Res, 2019.

PubMed 30522147 ↗DOI 10.1055/a-0774-8809 ↗

CancerNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.